Baselake group (TXMD) discloses 6.8% beneficial stake in TherapeuticsMD common stock

Rhea-AI Filing Summary

Baselake Partners, LP, together with Baselake Management, LLC and David Paolella, reports beneficial ownership of common stock of TherapeuticsMD, Inc. This amendment states that the reporting group may be deemed to beneficially own 790,703 shares of common stock, representing 6.8% of the class.

The shares are held directly by Baselake Partners, LP, with Baselake Management, LLC acting as investment manager and David Paolella as managing member. All three reporting persons have shared voting and dispositive power over these shares and no sole voting or dispositive power. The ownership percentage is based on 11,574,362 shares outstanding as of May 11, 2026, as referenced from TherapeuticsMD's quarterly report. Each reporting person disclaims beneficial ownership except to the extent of any pecuniary interest.

Key Figures

Shares beneficially owned: 790,703 shares Ownership percentage: 6.8% Shares outstanding: 11,574,362 shares +4 more

7 metrics

Shares beneficially owned 790,703 shares Common stock of TherapeuticsMD, Inc. reported by Baselake Partners, LP and related persons

Ownership percentage 6.8% Percent of TherapeuticsMD common stock class held by the reporting group

Shares outstanding 11,574,362 shares TherapeuticsMD common shares issued and outstanding as of May 11, 2026

Sole voting power 0 shares Each reporting person's sole power to vote or direct the vote

Shared voting power 790,703 shares Shares over which each reporting person has shared voting power

Shared dispositive power 790,703 shares Shares over which each reporting person has shared dispositive power

Reporting date of amendment 06/30/2026 Date reference appearing on the amended Schedule 13G

Key Terms

beneficial ownership, shared voting power, dispositive power, Section 13 of the Securities Exchange Act of 1934, +1 more

5 terms

beneficial ownership regulatory

"This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the Shares"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

shared voting power regulatory

"may be deemed to have shared voting and dispositive power with respect to the Shares"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

dispositive power regulatory

"shared voting and dispositive power with respect to the Shares owned directly by the Fund"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Section 13 of the Securities Exchange Act of 1934 regulatory

"for purposes of Section 13 of the Securities Exchange Act of 1934, as amended"

Schedule 13G regulatory

"This report shall not be deemed an admission that the Reporting Persons are beneficial owners"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/05/2026 - 04:42 PM Accepted by SEC EDGAR 08/05/2026 - 04:41 PM Learn about SEC filing dates

FAQ

What percentage of TherapeuticsMD (TXMD) does Baselake Partners report owning?

Baselake Partners, LP and related reporting persons report beneficial ownership of 6.8% of TherapeuticsMD's common stock, based on 11,574,362 shares outstanding as of May 11, 2026.

How many TherapeuticsMD (TXMD) shares are reported by Baselake Partners?

The reporting group states that Baselake Partners, LP beneficially owns 790,703 shares of TherapeuticsMD common stock, with shared voting and dispositive power over all of these shares and no sole power.

Who are the reporting persons in this Schedule 13G/A for TXMD?

The filing lists Baselake Partners, LP, Baselake Management, LLC, and David Paolella as reporting persons, reflecting the fund, its investment manager, and the managing member, respectively.

How is voting power over TherapeuticsMD (TXMD) shares allocated among the reporting persons?

Each reporting person has 0 sole voting power and 790,703 shares of shared voting power, meaning voting authority is shared across Baselake Partners, Baselake Management, and David Paolella for the same block of shares.

On what share count is Baselake’s 6.8% TXMD ownership based?

The 6.8% ownership is calculated using 11,574,362 TherapeuticsMD common shares issued and outstanding as of May 11, 2026, as stated in the company's Form 10-Q.

Do the Baselake reporting persons admit beneficial ownership of all TXMD shares reported?

No. The filing states the reporting persons disclaim beneficial ownership of the reported shares except to the extent of their pecuniary interest, despite being deemed to share voting and dispositive power.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

TherapeuticsMD, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

88338N206

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 88338N206

1

Names of Reporting Persons

Baselake Partners, LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 790,703.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 790,703.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

790,703.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Please see note in Item 4(a)

SCHEDULE 13G

CUSIP Number(s): 88338N206

1

Names of Reporting Persons

Baselake Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 790,703.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 790,703.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

790,703.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

IA, OO

Comment for Type of Reporting Person: Please see note in Item 4(a)

SCHEDULE 13G

CUSIP Number(s): 88338N206

1

Names of Reporting Persons

David Paolella

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 790,703.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 790,703.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

790,703.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.8 %

12

Type of Reporting Person (See Instructions)

HC, IN

Comment for Type of Reporting Person: Please see note in Item 4(a)

SCHEDULE 13G

Item 1.
(a)	Name of issuer: TherapeuticsMD, Inc.
(b)	Address of issuer's principal executive offices: 951 Yamato Road, Suite 220 Boca Raton, Florida 33431
Item 2.
(a)	Name of person filing: Baselake Partners, LP* Baselake Management, LLC* David Paolella*
(b)	Address or principal business office or, if none, residence: 3155 W. Big Beaver Road, Suite 207, Troy, Michigan 48084
(c)	Citizenship: Baselake Partners, LP - Delaware Baselake Management, LLC - Delaware David Paolella - United States of America
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 88338N206
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: Baselake Partners, LP - 790,703* Baselake Management, LLC - 790,703* David Paolella - 790,703* The Common Stock (the "Shares") reported herein are held by Baselake Partners, LP (the "Fund"). Baselake Management, LLC serves as the investment manager to the Fund (the "Investment Manager"). David Paolella serves as the managing member of the Investment Manager (the "Managing Member," and collectively with the Fund and the Investment Manager, the "Reporting Persons"). By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the Shares owned directly by the Fund. The percentages reported herein are calculated based upon a statement in the Issuer's 10-Q, indicating that there are 11,574,362 Shares issued and outstanding as of May 11, 2026. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the Shares for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of the Reporting Persons pecuniary interest therein.
(b)	Percent of class: Baselake Partners, LP - 6.8%* Baselake Management, LLC - 6.8%* David Paolella - 6.8%*
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Baselake Partners, LP - 0 Baselake Management, LLC - 0 David Paolella - 0
	(ii) Shared power to vote or to direct the vote: Baselake Partners, LP - 790,703* Baselake Management, LLC - 790,703* David Paolella - 790,703*
	(iii) Sole power to dispose or to direct the disposition of: Baselake Partners, LP - 0 Baselake Management, LLC - 0 David Paolella - 0
	(iv) Shared power to dispose or to direct the disposition of: Baselake Partners, LP - 790,703* Baselake Management, LLC - 790,703* David Paolella - 790,703*
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Baselake Partners, LP

Signature:	/s/ David Paolella
Name/Title:	David Paolella, Managing Member of Baselake Management, LLC, its investment manager
Date:	08/05/2026

Baselake Management, LLC

Signature:	/s/ David Paolella
Name/Title:	David Paolella, Managing Member
Date:	08/05/2026

David Paolella

Signature:	/s/ David Paolella
Name/Title:	Individually
Date:	08/05/2026

Exhibit Information

Exhibit I - JOINT FILING STATEMENT